SG11201807146SA - 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative - Google Patents
5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivativeInfo
- Publication number
- SG11201807146SA SG11201807146SA SG11201807146SA SG11201807146SA SG11201807146SA SG 11201807146S A SG11201807146S A SG 11201807146SA SG 11201807146S A SG11201807146S A SG 11201807146SA SG 11201807146S A SG11201807146S A SG 11201807146SA SG 11201807146S A SG11201807146S A SG 11201807146SA
- Authority
- SG
- Singapore
- Prior art keywords
- osaka
- shi
- otedori
- chuo
- otsuka
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
WO 17 / 15 065 4 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/150654 Al 8 September 2017 (08.09.2017) WIPO I PCT 1111111111111101110101011111010111110 01111001101111111001111111111111110111111 (51) International Patent Classification: C07D 237/02 (2006.01) A61K 31/50 (2006.01) C07D 237/14 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/JP2017/008246 (22) International Filing Date: 2 March 2017 (02.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2016-042535 4 March 2016 (04.03.2016) JP (71) Applicant: OTSUKA PHARMACEUTICAL CO., LTD. [JP/JP]; 2-9, Kanda Tsukasa-machi, Chiyoda-ku, Tokyo, 1018535 (JP). (72) Inventors: KATOH, Takahiro; c/o OTSUKA PHARMA- CEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka- shi, Osaka, 5400021 (JP). IIDA, Masatoshi; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo- ku, Osaka-shi, Osaka, 5400021 (JP). TERAUCHI, Yuki; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). YAMAGUCHI, Kazuya; c/o OTSUKA PHARMACEUT- ICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). HIROSE, Toshiyuki; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo- ku, Osaka-shi, Osaka, 5400021 (JP). YOKOYAMA, Fu- miharu; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). NISHIMORI, Hikaru; c/o OTSUKA PHARMA- CEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka- shi, Osaka, 5400021 (JP). OBUCHI, Yutaka; c/o OT- SUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). NABESHIMA, Hiroshi; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). TAKAKI, Emiri; c/o OTSUKA PHARMACEUTIC- AL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). (74) Agents: SAMEJIMA, Mutsumi et al.; AOYAMA & PARTNERS, Umeda Hankyu Bldg. Office Tower, 8-1, Kakuda-cho, Kita-ku, Osaka-shi, Osaka, 5300017 (JP). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, [Continued on next page] (54) Title: 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE R 2 ( 1 ) (57) : The present invention provides an agent for treating malignant tumor, comprising a compound of formula (1): wherein R 1 to R 4 are hydrogen atom, halogen, or etc., Y is optionally-substituted alkylene group or etc. WO 2017/150654 Al MIDEDIM000101011101010M0E001101H1001111111110110111111 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Published: GW, KM, ML, MR, NE, SN, TD, TG). — with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016042535 | 2016-03-04 | ||
| PCT/JP2017/008246 WO2017150654A1 (en) | 2016-03-04 | 2017-03-02 | 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807146SA true SG11201807146SA (en) | 2018-09-27 |
Family
ID=58347859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807146SA SG11201807146SA (en) | 2016-03-04 | 2017-03-02 | 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10611731B2 (en) |
| EP (1) | EP3423440B9 (en) |
| JP (1) | JP6596595B2 (en) |
| KR (1) | KR102350772B1 (en) |
| CN (1) | CN108779076B (en) |
| AU (2) | AU2017226674B2 (en) |
| CA (1) | CA3015331A1 (en) |
| CY (1) | CY1123927T1 (en) |
| DK (1) | DK3423440T3 (en) |
| EA (1) | EA036423B1 (en) |
| ES (1) | ES2862177T3 (en) |
| HR (1) | HRP20210395T1 (en) |
| HU (1) | HUE053358T2 (en) |
| IL (1) | IL261225B (en) |
| LT (1) | LT3423440T (en) |
| MX (1) | MX2018010535A (en) |
| MY (1) | MY196801A (en) |
| NZ (1) | NZ745688A (en) |
| PH (1) | PH12018501873A1 (en) |
| PL (1) | PL3423440T3 (en) |
| PT (1) | PT3423440T (en) |
| RS (1) | RS61593B1 (en) |
| SA (1) | SA518392275B1 (en) |
| SG (1) | SG11201807146SA (en) |
| SI (1) | SI3423440T1 (en) |
| TW (1) | TWI731041B (en) |
| WO (1) | WO2017150654A1 (en) |
| ZA (1) | ZA201805791B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7104588B2 (en) * | 2017-09-01 | 2022-07-21 | 大塚製薬株式会社 | A therapeutic agent for malignant tumors containing a 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazine-3-one derivative |
| EP3917915A1 (en) * | 2019-02-01 | 2021-12-08 | Bayer Aktiengesellschaft | 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63145272A (en) * | 1986-12-09 | 1988-06-17 | Morishita Seiyaku Kk | 4,5-dihydro-6-(4-substituted phenyl)-3(2h)-pyridazinone derivative |
| US5100892A (en) * | 1990-11-13 | 1992-03-31 | Glaxo Inc. | Dihydropyridine vasodilator agents |
| US5563143A (en) * | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| CN1136197C (en) * | 1996-05-30 | 2004-01-28 | 霍夫曼-拉罗奇有限公司 | Novel pyridajinone derivatives |
| CA2588949A1 (en) | 2004-11-30 | 2006-06-08 | Artesian Therapeutics, Inc. | Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure |
| US20100160335A1 (en) | 2007-06-19 | 2010-06-24 | Kyorin Pharmaceutical Co., Ltd. | Pyridazinone derivative and pde inhibitor containing the same as active ingredient |
| CN101537006B (en) * | 2008-03-18 | 2012-06-06 | 中国科学院上海药物研究所 | Application of pyridazinone compounds in preparing antitumor drugs |
| US9890127B2 (en) | 2013-03-11 | 2018-02-13 | The Broad Institute, Inc. | Compounds and compositions for the treatment of cancer |
-
2017
- 2017-03-02 AU AU2017226674A patent/AU2017226674B2/en active Active
- 2017-03-02 MY MYPI2018703021A patent/MY196801A/en unknown
- 2017-03-02 MX MX2018010535A patent/MX2018010535A/en unknown
- 2017-03-02 EP EP17711366.9A patent/EP3423440B9/en active Active
- 2017-03-02 SG SG11201807146SA patent/SG11201807146SA/en unknown
- 2017-03-02 HU HUE17711366A patent/HUE053358T2/en unknown
- 2017-03-02 NZ NZ745688A patent/NZ745688A/en unknown
- 2017-03-02 PL PL17711366T patent/PL3423440T3/en unknown
- 2017-03-02 CA CA3015331A patent/CA3015331A1/en active Pending
- 2017-03-02 KR KR1020187028010A patent/KR102350772B1/en active IP Right Grant
- 2017-03-02 SI SI201730668T patent/SI3423440T1/en unknown
- 2017-03-02 WO PCT/JP2017/008246 patent/WO2017150654A1/en active Application Filing
- 2017-03-02 EA EA201891987A patent/EA036423B1/en not_active IP Right Cessation
- 2017-03-02 CN CN201780013870.4A patent/CN108779076B/en active Active
- 2017-03-02 RS RS20210193A patent/RS61593B1/en unknown
- 2017-03-02 TW TW106106813A patent/TWI731041B/en active
- 2017-03-02 ES ES17711366T patent/ES2862177T3/en active Active
- 2017-03-02 DK DK17711366.9T patent/DK3423440T3/en active
- 2017-03-02 US US16/081,260 patent/US10611731B2/en active Active
- 2017-03-02 JP JP2018544577A patent/JP6596595B2/en active Active
- 2017-03-02 PT PT177113669T patent/PT3423440T/en unknown
- 2017-03-02 LT LTEP17711366.9T patent/LT3423440T/en unknown
-
2018
- 2018-08-19 IL IL261225A patent/IL261225B/en unknown
- 2018-08-26 SA SA518392275A patent/SA518392275B1/en unknown
- 2018-08-29 ZA ZA2018/05791A patent/ZA201805791B/en unknown
- 2018-09-03 PH PH12018501873A patent/PH12018501873A1/en unknown
-
2020
- 2020-02-12 US US16/788,894 patent/US20200181092A1/en not_active Abandoned
-
2021
- 2021-02-22 AU AU2021201135A patent/AU2021201135B2/en active Active
- 2021-02-23 US US17/182,549 patent/US20210171472A1/en active Pending
- 2021-02-24 CY CY20211100155T patent/CY1123927T1/en unknown
- 2021-03-08 HR HRP20210395TT patent/HRP20210395T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201804674UA (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201408739VA (en) | Inhibitors of hepatitis c virus | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201906163TA (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201909083UA (en) | Piperidines as covalent menin inhibitors | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201406973PA (en) | Complement pathway modulators and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201906222WA (en) | Jak1 selective inhibitors |